A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Inclusion Criteria:

* Fully aware of the research and voluntarily signed informed consent (informed consent must be signed prior to the execution of any required test procedure);
* Patients received removal of biliary tract cancers that have been confirmed by histology or cytology, including intrahepatic bile duct carcinoma (IHCC), extrahepatic bile duct cancer (EHCC), and gallbladder cancer(GBC);
* Normal function of major organs that meets the following criteria:

Blood routine examination:

HB≥90 g/L； ANC≥1.5×109/L； PLT≥60×109/L；

Biochemical examination:

ALB ≥29 g/L； ALT and AST\<2.5ULN； TBIL ≤2ULN； Creatinine≤1.5ULN;

* ECOG physical condition scores 0 or 1;
* Fertile male or female patients volunteer to use effective contraception methods during the research period, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc.
* Fertile and non-lactational female who show negative in serum or urine pregnancy test within 7 days before inclusion for the study.

Exclusion Criteria:

* Those who received approved or on-going anti-tumor therapy within 4 weeks before the research;
* Those who received other anti-angiogenic tyrosine kinase inhibitors or monoclonal antibodies that had been approved or under study before the research;
* Abnormal laboratory tests that have significant clinical implication;
* International normalized ratio (INR) ≥ 1.5 or partially activated prothrombin time (APTT) ≥ 1.5 × ULN;
* The patient's current serum potassium, serum magnesium, or serum calcium is below the normal reference range of laboratory test (whether supplemented or not), or \>CTCAE grade 1;
* Patients currently suffering from hypertension that cannot be controlled with drugs;
* The researchers conclude electrolyte abnormalities that are clinically significant;
* There is severe bleeding or hemoptysis in the past or at current stage, or there are thromboembolic events within 12 months;
* Cardiovascular diseases that are clinically significant;
* ECG showed QTcB interval ≥ 480 milliseconds in resting state;
* Suffering from other malignant tumors in the past 5 years, excluding basal cell carcinoma or squamous cell carcinoma after receiving radical surgery, or carcinoma in situ of cervix;
* Active or uncontrollable serious infection (≥ CTCAE grade 2 infection), including but not limited to human immunodeficiency virus (HIV) infection;
* Known history of liver disease with evident significance;
* The patient currently has brain metastasis or spinal compression, except individual cases.